We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Nilpotency concepts for skew braces are among the main tools with which we are nowadays classifying certain special solutions of the Yang–Baxter equation, a consistency equation that plays a relevant role in quantum statistical mechanics and in many areas of mathematics. In this context, two relevant questions have been raised in F. Cedó, A. Smoktunowicz and L. Vendramin (Skew left braces of nilpotent type. Proc. Lond. Math. Soc. (3) 118 (2019), 1367–1392) (see questions 2.34 and 2.35) concerning right- and central nilpotency. The aim of this short note is to give a negative answer to both questions: thus, we show that a finite strong-nil brace B need not be right-nilpotent. On a positive note, we show that there is one (and only one, by our examples) special case of the previous questions that actually holds. In fact, we show that if B is a skew brace of nilpotent type and $b\ \ast \ b=0$ for all $b\in B$, then B is centrally nilpotent.
The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin’s efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the methodological constraints of existing research.
An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin’s efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin’s safety, long-term efficacy, and optimal dosage remain unclear due to previous trials’ limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin’s full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin’s implementation in healthcare systems.
We investigated the impact of COVID-19 restrictions on the duration of untreated psychosis (DUP). First-episode psychosis admissions (n = 101) to the STEP Clinic in Connecticut showed DUP reduction (P = 0.0015) during the pandemic, with the median reducing from 208 days pre-pandemic to 56 days in the early pandemic period, and subsequently increasing to 154 days (P = 0.0281). Time from psychosis onset to antipsychotic prescription decreased significantly in the pandemic (P = 0.0183), with the median falling from 117 to 35 days. This cohort study demonstrates an association between greater pandemic restrictions and marked DUP reduction, and provides insights for future early detection efforts.
Administrative innovations in South-west Asia during the fourth millennium BC, including the cylinder seals that were rolled on the earliest clay tablets, laid the foundations for proto-cuneiform script, one of the first writing systems. Seals were rich in iconography, but little research has focused on the potential influence of specific motifs on the development of the sign-based proto-cuneiform script. Here, the authors identify symbolic precursors to fundamental proto-cuneiform signs among late pre-literate seal motifs that describe the transportation of vessels and textiles, highlighting the synergy of early systems of clay-based communication.